Trial Profile
Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain metastases; Liver metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2023 Planned End Date changed from 17 Sep 2023 to 30 Sep 2025.
- 26 Aug 2023 Planned primary completion date changed from 17 Sep 2023 to 30 Sep 2025.
- 22 Feb 2023 Planned End Date changed from 17 Sep 2022 to 17 Sep 2023.